Table 3.
Rectal cancer pooled analysis: 5-year survival rates by treatment method for intermediate-risk, moderately high-risk, and high-risk patients.
| Risk group/TN stage | S + CT(%) | RT + bolus CT*(%) | RT + PVI CT(%) | RT + bolus CT† (%) |
|---|---|---|---|---|
| Overall survival | ||||
| Intermediate risk | ||||
| T1-2N1 (n = 355) | 85 | 83 | 78 | 82 |
| T3N0 (n = 1,060) | 84 | 76 | 80 | 74 |
| Moderately high risk | ||||
| T1-2N2 (n = 226) | 43 | 55 | 44 | 77 |
| T3N1 (n = 887) | 52 | 61 | 73 | 63 |
| T4N0 (n = 111) | 70 (10)‡ | 58 | 80 | 67 |
| High risk | ||||
| T3N2 (n = 935) | 45 | 42 | 46 | 50 |
| T4N1 (n = 62) | 29 (7)‡ | 57 | 0 (1)‡ | 31 |
| T4N2 (n = 108) | 25 (4)‡ | 29 | 53 | 44 |
| Disease-free survival | ||||
| Intermediate risk | ||||
| T1-2N1 (n = 355) | 78 | 78 | 76 | 75 |
| T3N0 (n = 1,058) | 69 | 63 | 75 | 66 |
| Moderately high risk | ||||
| T1-2N2 (n = 226) | 36 | 48 | 39 | 66 |
| T3N1 (n = 881) | 43 | 51 | 63 | 51 |
| T4N0 (n = 111) | 50 (10)‡ | 55 | 70 | 55 |
| High risk‡ | ||||
| T3N2 (n = 929) | 36 | 34 | 30 | 42 |
| T4N1 (n = 62) | 14 (7)‡ | 57 | 0 (1)‡ | 26 |
| T4N2 (n = 108) | 25 (4)‡ | 26 | 47 | 31 |
Modified from Gunderson et al12
*
NCCTG and NSABP trials
†
INT 0114
‡
Number of patients at risk
Abbreviations: CT = chemotherapy; NCCTG = North Central Cancer Treatment Group; NSABP = National Surgical Adjuvant Breast and Bowel Project; PVI = protracted venous infusion; RT = radiotherapy; S = surgery; TN = tumor, node.